Continuing its interest in targeted protein degradation space, Sanofi has entered into a multi-programme strategic collaboration with Kymera Therapeutics to develop and commercialise IRAK4 degraders in inflammation and immunology indications. The deal, which is worth upto US$2.33 B, will combine Sanofi’s clinical and patient reach capabilities with Kymera’s Pegasus™ technology platform and signaling pathway expertise. Kymera will retain global rights to its IRAK4 programme in oncology indications.